Burkitt lymphoma

Overview

Burkitt lymphoma (BL) is a highly aggressive, fast-growing form of non-Hodgkin lymphoma (NHL) that originates from B-lymphocytes (B-cells). It is characterized by a specific chromosomal translocation involving the MYC gene (usually t(8;14)), resulting in uncontrolled cellular proliferation. First described by Denis Burkitt in 1958 in African children presenting with jaw tumors, the disease is now recognized globally in three distinct clinical variants: Endemic, Sporadic, and Immunodeficiency-associated.

Despite its aggressive nature—often cited as one of the fastest-growing human tumors—Burkitt lymphoma is highly curable with modern, intensive multi-agent chemotherapy regimens. Cure rates exceed 90% in pediatric patients and approach 70–85% in adults, provided treatment is initiated promptly and supportive care is expertly managed.

Epidemiology and Clinical Variants

Understanding the three variants is crucial for risk assessment, differential diagnosis, and public health planning.

Key Epidemiological Facts:

• Incidence: Rare, accounting for 1–2% of all adult NHLs but 30–40% of pediatric NHLs.
• Gender: Male predominance (3:1 to 4:1 ratio) across all variants.
• HIV Era: Before effective antiretroviral therapy (ART), BL was an AIDS-defining illness. With ART, incidence has dropped, but risk remains elevated compared to the general population.

Etiology and Pathogenesis: The Molecular Engine

The hallmark of Burkitt lymphoma is the dysregulation of the MYC proto-oncogene (located at 8q24). MYC is a transcription factor controlling cell cycle progression, apoptosis, metabolism, and differentiation. In BL, a reciprocal translocation juxtaposes MYC next to immunoglobulin (Ig) gene enhancers, driving constitutive MYC overexpression.

The Classic Translocations

Clinical Pearl:** The specific Ig partner (Heavy vs. Light chain) does not significantly alter prognosis but is useful for diagnostic confirmation via Fluorescence In Situ Hybridization (FISH) or PCR.

The Role of Epstein-Barr Virus (EBV)

EBV is etiologically linked, particularly in the Endemic variant. The virus expresses latent proteins (EBNA1, LMP1/2A/2B) that:

1. Promote B-cell survival and proliferation.
2. Inhibit apoptosis.
3. May induce genomic instability (Activation-Induced Cytidine Deaminase – AID upregulation), increasing the likelihood of the MYC translocation.
4. Allow the tumor to evade immune surveillance (downregulation of HLA class I).

Cooperating Mutations

MYC translocation alone is insufficient for full malignant transformation. Secondary “hits” are almost universally present:

• TP53 mutations: ~30–40% of cases (associated with poorer prognosis/chemoresistance).
• ID3 mutations: ~40% (mutations in the ID3 gene, a negative regulator of E2A transcription factors, found in ~60% of sporadic cases).
• TCF3 mutations: ~70% (transcription factor 3).
• CCND3 mutations: Cyclin D3 mutations.
• SWI/SNF complex mutations: SMARCA4, ARID1A (chromatin remodeling).

How Does It Look? (Pathology, Histology, and Imaging)

This section details the visual and microscopic appearance of the disease, essential for diagnosis.

1. Gross Pathology (Macroscopic Appearance)

• Cut Surface: Tumors are typically soft, fleshy, and homogeneous, with a characteristic “fish-flesh” or “brain-like” consistency. They are usually grey-white to tan.
• Necrosis: Large tumors frequently exhibit central necrosis and hemorrhage due to outgrowth of blood supply (high metabolic rate).
• Capsule: Often lacks a true capsule; tends to infiltrate surrounding tissues (e.g., mesentery, bone cortex).
• Variant Specifics:
• Endemic: Massive jaw/maxillary tumors destroying bone, loosening teeth, protruding into oral cavity/nasopharynx.
• Sporadic: Bulky abdominal masses (ileocecal region “blind loop” syndrome), ovarian masses (mimicking ovarian cancer), renal masses.

2. Microscopic Histology (Light Microscopy)

The classic description is a “starry sky” pattern, though this is not exclusive to BL.

3. Immunophenotype (Immunohistochemistry / Flow Cytometry)

The immunophenotype reflects a Germinal Center B-cell (GCB) origin.

Diagnostic Pitfall: “Gray Zone” Lymphomas. Cases with MYC rearrangement but BCL2 protein expression (“Double Expressor”) or BCL2 translocation (“Double Hit”) fall into High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBCL-DH/TH). True BL is BCL2 negative (protein) and lacks BCL2/BCL6 rearrangements.

4. Cytogenetics and Molecular Diagnostics (Gold Standard)

• FISH (Fluorescence In Situ Hybridization): Gold standard for detecting MYC rearrangement (break-apart probe). Must confirm IGH/MYC fusion or MYC break-apart without concurrent BCL2/BCL6 rearrangements.
• Karyotyping: Identifies the specific translocation partner (t(8;14) vs variant) and complex karyotype (additional chromosomal abnormalities = worse prognosis).
• PCR / NGS: Detects ID3, TP53, TCF3 mutations; supports diagnosis in morphologically ambiguous cases.

5. Radiological Imaging (How it Looks on Scans)

Imaging defines stage, bulk, and organ involvement.

Symptoms and Clinical Presentation

Symptoms evolve rapidly—often over days to weeks—reflecting the tumor’s doubling time of 24–48 hours. Presentation varies significantly by variant and site.

A. Sporadic Variant (Most Common in Western Medicine)

1. Abdominal Syndrome (60–70% of cases)

• Pain: Colicky or constant right lower quadrant (RLQ) or periumbilical pain (ileocecal mass).
• Palpable Mass: Often detected by patient or clinician; firm, mobile or fixed.
• Obstruction: Nausea, vomiting, constipation, distension (mechanical small bowel obstruction).
• Intussusception: Telescoping of bowel (lead point = tumor); classic “currant jelly” stools in children.
• Perforation/Acute Abdomen: Necrotic tumor erodes bowel wall → peritonitis (surgical emergency).
• Gastrointestinal Bleeding: Occult or overt melena/hematochezia.

2. Genitourinary Involvement

• Ovarian Masses: Bilateral in 20–30% of females; mimics germ cell tumors or epithelial ovarian cancer. Presents with pelvic pain, distension, urinary frequency.
• Renal Involvement: Flank pain, hematuria, hypertension, renal failure (obstruction/infiltration).
• Testicular Involvement: Rare primary presentation; painless swelling.

3. Lymphadenopathy

• Usually abdominal/retroperitoneal nodes. Peripheral nodes (cervical, axillary, inguinal) less common at diagnosis than in DLBCL.

B. Endemic Variant (African/Equatorial)

• Maxillofacial/Jaw Tumors: Rapidly expanding, painless (initially) swelling of the maxilla, mandible, or orbit.
• Dental Symptoms: Loosening of teeth, malocclusion, gingival bleeding, displacement of erupting teeth.
• Orbital Involvement: Proptosis (bulging eye), ophthalmoplegia (double vision), vision loss.
• Abdominal Involvement: Also common (distal ileum, cecum, ovaries), often concurrent with jaw disease.

C. Immunodeficiency-Associated Variant

• HIV+ Patients: Often presents at higher Ann Arbor stage (III/IV). Higher rates of bone marrow involvement, CNS involvement, and extranodal disease (GI tract, liver, spleen).
• Post-Transplant (PTLD): Often early post-transplant (<1 year). Can be polymorphic or monomorphic (BL morphology). EBV-driven.

D. Systemic “B Symptoms” (Constitutional)

Present in 30–50% at diagnosis; indicate high tumor burden/advanced stage.

• Fever: >38°C (100.4°F), often drenching night sweats.
• Night Sweats: Profuse, requiring clothing/bedding changes.
• Weight Loss: >10% body weight in 6 months (unintentional).
• Fatigue: Profound, often due to anemia (marrow infiltration or chronic disease).

E. Neurological Symptoms (CNS Involviation)

• Incidence: 5–15% at diagnosis (higher in HIV+, testicular, breast, paranasal sinus primaries).
• Symptoms: Cranial nerve palsies (CN VII most common – facial droop), headache, nausea/vomiting (raised ICP), focal deficits (hemiparesis), seizures, confusion/encephalopathy.
• Meningeal Spread: Lymphomatous meningitis (positive cytology on LP).

F. Paraneoplastic / Metabolic Emergencies

• Tumor Lysis Syndrome (TLS): High Risk. Massive cell turnover releases potassium, phosphate, uric acid. Can occur spontaneously before chemo. Medical Emergency: Hyperkalemia (arrhythmia), Hyperphosphatemia → Hypocalcemia (tetany, seizure), Hyperuricemia → Acute Kidney Injury.
• Superior Vena Cava (SVC) Syndrome: Mediastinal bulk (rare in BL vs DLBCL).
• Spinal Cord Compression: Paraspinal mass/epidural extension.

Staging and Risk Stratification

Ann Arbor Staging System (Modified for NHL – Cotswolds)

Used universally for treatment planning.

Suffixes:

• A: No B symptoms.
• B: B symptoms present (Fever, Night Sweats, Weight Loss).
• E: Contiguous extranodal extension.
• X: Bulky Disease (Definitions vary: Pediatric >6cm or >1/3 thoracic diameter; Adult often >10cm).

Risk Stratification Systems

Treatment intensity is tailored to risk.

1. Murphy/St. Jude (Pediatric/Adolescent) – Historical/Standard

• Low Risk (Group A/B): Resected Stage I/II (complete resection).
• Intermediate Risk (Group C): Unresected Stage I/II, Stage III, Stage IV with Low LDH & No CNS/BM involvement.
• High Risk (Group D): Stage IV with High LDH OR CNS involvement (CNS+) OR Bone Marrow involvement >25% (BM+).

2. International Prognostic Index (IPI) – Adults

Used for DLBCL but adapted; less specific for BL biology.

• Factors: Age >60, Stage III/IV, LDH > Normal, ECOG PS >1, >1 Extranodal site.

3. Burkitt-Specific Risk Factors (Modern Consensus)

• CNS Disease (CNS+): CSF positive, parenchymal lesion, cranial nerve palsy.
• Bone Marrow Involvement (BM+): >5% (or >25% for high risk).
• Lactate Dehydrogenase (LDH): >2x or >3x Upper Limit of Normal (ULN).
• Age: >40 years (worse tolerance/toxicity).
• Performance Status: ECOG >1.
• TP53 Mutation / Complex Karyotype: Emerging adverse markers.

Diagnostic Workup: Step-by-Step Algorithm

Urgent Note: Due to rapid growth and TLS risk, workup must be completed in days, not weeks. Biopsy should be performed before** steroids are given (steroids cause lymphoma lysis, obscuring diagnosis).

1. Tissue Diagnosis (Mandatory)

• Excisional Biopsy: Gold standard (lymph node or accessible mass). Preserves architecture.
• Core Needle Biopsy: Acceptable if excisional not feasible; must submit fresh tissue for flow cytometry/cytogenetics.
• FNA (Fine Needle Aspiration) / Cytology Alone: Insufficient for primary diagnosis (cannot assess architecture, Ki-67 reliably, or perform FISH).
• Bone Marrow Biopsy + Aspirate: Bilateral posterior iliac crests. Flow cytometry on aspirate.
• Lumbar Puncture (LP): Mandatory for all patients at diagnosis (CNS prophylaxis/treatment depends on result). Send: Cell count/diff, Protein, Glucose, Flow Cytometry, Cytology (x3 slides), MYC FISH/PCR if available.
• Testicular Ultrasound / Biopsy: If testicular abnormality on exam or PET.
• HIV Serology: Mandatory for all new diagnoses.

2. Laboratory Studies (Baseline & TLS Monitoring)

3. Imaging

• PET-CT (Skull base to mid-thigh): Standard staging & response assessment.
• MRI Brain/Spine: If CNS symptoms, LP positive, testicular/breast/sinus primary, or HIV+.
• Echocardiogram / MUGA: Baseline LVEF before Anthracyclines (Doxorubicin).

Treatment Principles: Speed and Intensity

Core Philosophy: Short duration, high intensity, no delays. Treatment cycles are typically 14–21 days apart (vs 21–28 for DLBCL). Dose reductions compromise cure rates.

1. Emergency Management: Tumor Lysis Syndrome (TLS) Prophylaxis

Initiate immediately upon clinical suspicion, before biopsy confirmation if TLS labs abnormal.

• Hydration: Aggressive IV fluids (3–4 L/m²/day) targeting urine output >100–200 mL/hr.
• Urate Lowering:
• Allopurinol: Prophylaxis for low/intermediate TLS risk.
• Rasburicase (Recombinant Urate Oxidase): First-line for High Risk (High LDH, bulky disease, renal impairment, hyperuricemia). Converts uric acid to allantoin. Contraindicated in G6PD deficiency.
• Electrolyte Monitoring: Q4–6h initially. Treat hyperkalemia (insulin/dextrose, kayexalate, dialysis), hypocalcemia (symptomatic only), hyperphosphatemia (binders, dialysis).
• Avoid: Potassium in IV fluids until K+ normal; Urine alkalinization (controversial, promotes CaPhos precipitation).

2. Pediatric/Adolescent Regimens (The Gold Standard)

Cure rates >90%. Basis for adult protocols.

Key Drugs:

• Cyclophosphamide: Alkylator (backbone).
• High-Dose Methotrexate (HD-MTX): 1–8 g/m² + Leucovorin rescue. Crosses BBB (CNS prophylaxis/treatment).
• Cytarabine (Ara-C): High-dose (1–3 g/m²). Critical for CNS penetration.
• Doxorubicin: Anthracycline (cardiotoxicity monitoring).
• Intrathecal (IT) Chemo: Methotrexate + Cytarabine + Hydrocortisone. Essential.

3. Adult Regimens (Adapting Pediatric Success)

Historically, adults fared worse due to dose reductions, toxicity, and use of CHOP (inadequate for BL). Modern protocols use pediatric-inspired regimens.

Rituximab (Anti-CD20):** Standard addition in adults. In pediatrics, benefit less clear in low/intermediate risk (added toxicity/infection risk), often reserved for high risk or relapse.

4. CNS Directed Therapy

• Prophylaxis (CNS-): Intrathecal (IT) Chemotherapy (Methotrexate 12mg + Ara-C 30mg + Hydrocortisone 15mg) repeated per protocol (typically 4–8 doses).
• Treatment (CNS+): High-dose Methotrexate (3–8 g/m²) + High-dose Cytarabine (2–3 g/m²) + Frequent IT Chemo (e.g., 2x/week until clear, then weekly). Cranial Radiation (24 Gy) reserved for refractory CNS disease or inability to give systemic HD-MTX/Ara-C.

5. HIV-Associated Burkitt Lymphoma

• ART MUST CONTINUE throughout chemotherapy (do not stop).
• Regimen: Dose-adjusted EPOCH-R (DA-EPOCH-R) or CODOX-M/IVAC with G-CSF support.
• Infection Prophylaxis: Critical.
• PJP: TMP-SMX (or Dapsone/Atovaquone).
• Antivirals: Acyclovir/Valacyclovir (HSV/VZV).
• Antifungals: Posaconazole/Voriconazole (prolonged neutropenia).
• G-CSF: Primary prophylaxis mandatory (pegfilgrastim or daily filgrastim).
• Drug Interactions: Azole antifungals + Protease Inhibitors/NNRTIs + Chemo (CYP3A4). Requires PharmD management.

6. Relapsed/Refractory Disease

• Prognosis: Poor (OS < 30%).
• Salvage Chemo: R-ICE, R-DHAP, R-GemOx, R-HyperCVAD.
• Consolidation: High-Dose Chemotherapy (HDT) + Autologous Stem Cell Transplant (ASCT) if chemo-sensitive (PR/CR). Allogeneic SCT considered for chemorefractory or early relapse post-auto.
• Novel Agents (Clinical Trials Preferred):
• CAR T-cell Therapy (Axicabtagene, Tisagenlecleucel, Lisocabtagene) – Active in aggressive B-NHL.
• Bispecific Antibodies (Glofitamab, Epcoritamab).
• BTK Inhibitors (Ibrutinib – limited single agent activity in BL).
• BCL2 Inhibitors (Venetoclax) – Rational in MYC/BCL2 double expressor/hit, less clear in true BL (BCL2 neg).

Supportive Care: The Backbone of Survival

Intensive chemo causes profound myelosuppression (neutropenia 10–14 days/cycle).

Prognosis and Survival Outcomes

Late Effects (Survivorship Focus)

• Cardiotoxicity: Anthracycline cardiomyopathy (systolic/diastolic dysfunction) – lifelong echo surveillance.
• Secondary Malignancies: AML/MDS (Alkylators/Etoposide/Radiation), Solid tumors (Radiation fields).
• Neurocognitive: HD-MTX/IT chemo/Cranial RT → leukoencephalopathy, executive dysfunction (esp. pediatrics).
• Endocrine: Hypogonadism, Infertility, Thyroid dysfunction (neck RT), Growth hormone deficiency (pediatrics).
• Renal: Chronic kidney disease (Cisplatin/Ifosfamide/TLS nephropathy).
• Psychosocial: Anxiety, PTSD, financial toxicity, insurance discrimination.

Differential Diagnosis: “The Blue Cell Tumors”

Frequently Asked Questions (FAQ)

Q: Is Burkitt lymphoma hereditary?

A: No. It is not an inherited genetic syndrome. It arises from acquired somatic mutations (MYC translocation, ID3/TP53 mutations). However, immunodeficiency states (familial or acquired) increase risk.

Q: Can Burkitt lymphoma be prevented?

A: No specific prevention for sporadic BL. In endemic areas, malaria control and potential future EBV vaccination may reduce incidence. In HIV, effective ART maintains immune surveillance, drastically lowering risk.

Q: Why is Rituximab not standard in all pediatric protocols?

A: Pediatric cure rates with chemo alone are already >90%. Adding Rituximab increases cost, infusion reactions, infection risk (hypogammaglobulinemia), and delays chemo cycles. It is used in high-risk/relapsed pediatric cases.

Q: What is “Double Hit” Lymphoma vs Burkitt?

A: “Double Hit” (HGBCL-DH) has MYC AND BCL2 (and/or BCL6) translocations. True Burkitt has only a MYC translocation (usually IGH-MYC) and is BCL2 protein negative. Double Hit behaves more aggressively/resistant than BL.

Q: Can adults be treated with pediatric protocols?

A: Yes, and they should be. “Pediatric-inspired” regimens (CODOX-M/IVAC, Hyper-CVAD, LMB) are the standard of care for fit adults up to age 70-75. CHOP/R-CHOP is considered substandard.

Q: What happens if I miss a chemo cycle due to low counts?

A: Do not delay. Growth factor (G-CSF) support allows count recovery. Dose reductions are preferred over delays if toxicity severe, but schedule density (dose intensity) is the #1 predictor of cure. Discuss with oncologist immediately.

Q: Is CNS prophylaxis really necessary if my LP is negative?

A: Absolutely. BL has high tropism for CNS. Without prophylaxis, CNS relapse rate is 20–30%. With IT chemo + systemic HD-MTX/Ara-C, it drops to <3–5%.

Glossary of Key Terms

• AID (Activation-Induced Cytidine Deaminase): Enzyme mediating somatic hypermutation and class-switch recombination in B-cells; off-target activity causes MYC translocations.
• Ann Arbor Staging: Classification system for lymphoma extent (I–IV).
• ASCT (Autologous Stem Cell Transplant): High-dose chemo + rescue with patient’s own stem cells.
• BCL2: Anti-apoptotic protein; negative in BL, positive in Follicular Lymphoma and most DLBCL.
• CNS Prophylaxis: Treatment to prevent Central Nervous System relapse (IT chemo, HD-MTX).
• COP/COPP: Cyclophosphamide, Vincristine, Prednisone (+/- Procarbazine).
• Cytogenetics: Study of chromosomes (Karyotype, FISH).
• DLBCL: Diffuse Large B-Cell Lymphoma (most common NHL).
• ECOG PS: Eastern Cooperative Oncology Group Performance Status (0–5 scale of function).
• EBV: Epstein-Barr Virus (Human Herpesvirus 4).
• FISH: Fluorescence In Situ Hybridization (DNA probe test for translocations).
• GCB: Germinal Center B-Cell (cell of origin subtype).
• HD-MTX: High-Dose Methotrexate (>500 mg/m², usually 1–8 g/m²).
• HGBCL: High-Grade B-Cell Lymphoma (Double/Triple Hit).
• IPI: International Prognostic Index.
• IT Chemo: Intrathecal Chemotherapy (into CSF via Lumbar Puncture or Ommaya reservoir).
• Ki-67 (MIB-1): Nuclear proliferation marker; ~100% in BL.
• LDH: Lactate Dehydrogenase (surrogate for tumor burden/turnover).
• MYC: Proto-oncogene on 8q24; driver of proliferation.
• PET-CT: Positron Emission Tomography / Computed Tomography (FDG-avidity).
• TLS: Tumor Lysis Syndrome (metabolic emergency from rapid cell death).
• TP53: Tumor suppressor gene (“Guardian of the Genome”); mutated in ~30% BL.

References

1. Alaggio, R., Amador, C., Anagnostopoulos, I. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720–1748. doi:10.1038/s41375-022-01613-1.
2. Swerdlow, S.H., Campo, E., Pileri, S.A. et al. (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edn. Lyon: IARC Press.
3. Dunleavy, K. and Wilson, W.H. (2014) ‘Burkitt lymphoma: current treatment strategies’, Current Treatment Options in Oncology, 15(1), pp. 139–152. doi:10.1007/s11864-013-0264-9.
4. Roschewski, M., Dunleavy, K. and Wilson, W.H. (2014) ‘Burkitt lymphoma in the adult patient’, Hematology/Oncology Clinics of North America, 28(5), pp. 863–877. doi:10.1016/j.hoc.2014.04.006.
5. Sandlund, J.T., Downing, J.R. and Crist, W.M. (1996) ‘Non-Hodgkin’s lymphoma in childhood’, New England Journal of Medicine, 334(19), pp. 1238–1248. doi:10.1056/NEJM199605093341907. (Classic seminal review).
6. Burkitt, D. (1958) ‘A sarcoma involving the jaws in African children’, British Journal of Surgery, 46(197), pp. 218–223. doi:10.1002/bjs.18004619704.
7. Love, C., Sun, Z., Jima, D. et al. (2012) ‘The genetic landscape of mutations in Burkitt lymphoma’, Nature Genetics, 44(12), pp. 1321–1325. doi:10.1038/ng.2468.
8. Schmitz, R., Hansmann, M.-L., Bohle, V. et al. (2012) ‘Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics’, Nature, 490(7418), pp. 116–120. doi:10.1038/nature11378.
9. National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): B-Cell Lymphomas. Version 5.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (Accessed: 15 October 2023).
10. European Society for Medical Oncology (ESMO) (2022) ‘Burkitt lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 33(8), pp. 762–775. doi:10.1016/j.annonc.2022.04.010.
11. Cortelazzo, S., Ponzoni, M. and Ferreri, A.J.M. (2020) ‘Burkitt lymphoma in adults’, Hematology, 2020(1), pp. 299–306. doi:10.1182/hematology.2020000112.
12. Hesseling, P.B., Broadhead, R., Molyneux, E. et al. (2009) ‘Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate’, Annals of Tropical Paediatrics, 29(4), pp. 229–236. doi:10.1179/146532809X12510418537694.
13. Medici, M., Waanders, E. and Visser, T.P. et al. (2019) ‘Treatment of adult Burkitt lymphoma with dose-adjusted EPOCH-R’, Blood Advances, 3(10), pp. 1609–1616. doi:10.1182/bloodadvances.2018030123.
14. Cairo, M.S. and Bishop, M. (2004) ‘Tumour lysis syndrome: new therapeutic strategies and classification’, British Journal of Haematology, 127(1), pp. 3–11. doi:10.1111/j.1365-2141.2004.05139.x.
15. Howell, S.J., Halsey, J., Wadsley, J. et al. (2019) ‘CODOX-M/IVAC vs. DA-EPOCH-R in adult Burkitt lymphoma: a retrospective multicentre UK study’, British Journal of Haematology, 187(3), pp. 357–366. doi:10.1111/bjh.16086.
16. Smith, A., Crouch, S., Lax, S. et al. (2019) ‘Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network’, British Journal of Cancer, 120(6), pp. 575–583. doi:10.1038/s41416-018-0385-5.
17. Odejide, O.O., Cronin, A.M., Zheng, J. et al. (2017) ‘Burkitt lymphoma in the United States: trends in incidence and survival’, Blood Advances, 1(15), pp. 1095–1102. doi:10.1182/bloodadvances.2017005907.
18. Evens, A.M., Helenowski, I., Ramsdale, E. et al. (2018) ‘Multicenter analysis of 828 adult Burkitt lymphoma patients: outcomes with dose-intensive therapy and rituximab’, Journal of Clinical Oncology, 36(18), pp. 1828–1836. doi:10.1200/JCO.2017.76.4764.
19. Bhatia, S., Landier, W., Hageman, L. et al. (2018) ‘Long-term survival outcomes in children with Burkitt lymphoma treated on FAB/LMB 96’, Journal of Clinical Oncology, 36(15_suppl), pp. 10005–10005. doi:10.1200/JCO.2018.36.15_suppl.10005.
20. Piccaluga, P.P., De Falco, G., Kustagi, M. et al. (2020) ‘The molecular landscape of Burkitt lymphoma: implications for diagnosis and therapy’, Journal of Clinical Oncology, 38(22), pp. 2541–2552. doi:10.1200/JCO.19.02456.

Disclaimer

If you suspect a medical emergency (e.g., Tumor Lysis Syndrome, Spinal Cord Compression, Severe Infection/Sepsis), call emergency services (911 in US) or go to the nearest Emergency Department immediately.